Literature DB >> 24942393

Reducing elevated plasma LDL cholesterol: the central role of the LDL receptor.

J Vincent1.   

Abstract

Elevated low-density lipoprotein cholesterol (LDL-C) is an established risk factor for cardiovascular disease (CVD), and reduction of elevated LDL-C reduces mortality in patients at risk. This benefit has evolved from the use of statins and knowledge of the LDL receptor (LDLR). The most potent drugs used for dyslipidemias act by mechanisms that involve this receptor. Advances in molecular genetics and understanding of the regulation of this receptor have revealed several pharmacological targets that are being explored to develop more targeted therapies for dyslipidemias.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24942393     DOI: 10.1038/clpt.2014.95

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  2 in total

1.  Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies.

Authors:  Ellen Q Wang; Jack F Bukowski; Carla Yunis; Charles L Shear; Paul M Ridker; Pamela F Schwartz; Daniel Baltrukonis
Journal:  BioDrugs       Date:  2019-10       Impact factor: 5.807

2.  Proteolysis of the low density lipoprotein receptor by bone morphogenetic protein-1 regulates cellular cholesterol uptake.

Authors:  Sreemoti Banerjee; Robert J Andrew; Christopher J Duff; Kate Fisher; Carolyn D Jackson; Catherine B Lawrence; Nobuyo Maeda; Daniel S Greenspan; Katherine A B Kellett; Nigel M Hooper
Journal:  Sci Rep       Date:  2019-08-06       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.